Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 2Withdrawn 1Terminated 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 14Lung Neoplasms 6Triple Negative Breast Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Pancreatic Neoplasms 3Colorectal Neoplasms 3Urinary Bladder Neoplasms 2Carcinoma, Renal Cell 2Uveal Melanoma 1Squamous Non-small Cell Lung Cancer 1Small Cell Lung Carcinoma 1Primary Myelofibrosis 1Polycythemia Vera 1Oropharyngeal Neoplasms 1Neoplasm, Residual 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1Microsatellite Instability 1Melanoma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Large B-Cell, Diffuse 1Liver Neoplasms 1Colonic Neoplasms 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Breast Cancer Female 1Biliary Tract Neoplasms 1Adenocarcinoma of Lung 1Adenocarcinoma Of Esophagus 1

Interventions

Fluorouracil 11Leucovorin 10Oxaliplatin 9Bevacizumab 6Irinotecan 5Capecitabine 3regorafenib 2aflibercept 2Folfox protocol 2Exercise 2Chemotherapy, Adjuvant 2Cetuximab 2Biopsy 2Atorvastatin 2tucatinib 1trifluridine tipiracil drug combination 1trastuzumab biosimilar HLX02 1sulindac sulfone 1sargramostim 1retrovector encoding mutant anti-cyclin G1 1poly ICLC 1pidilizumab 1pembrolizumab 1p53 peptide 264-272, human 1nilotinib 1monalizumab 1lonafarnib 1irofulven 1infigratinib 1grp protein, Drosophila 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Colonic Neoplasms × durvalumab × Clear all
NCT04145193 2020-09-21

Novel Oncology Therapies in Combination With Adjuvant Chemo in High-risk MSS-CRC

MedImmune LLC

Phase 2 Withdrawn
Gastrointestinal

Colonic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡